Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

Alexis Kramer

Pharma Editor

The Senate on Thursday confirmed Robert F. Kennedy Jr. as Secretary of Health and Human Services, putting a longtime anti-vaccination advocate at the helm of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Up­dat­ed: Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health pro­grams

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Sanofi faces $250M charge af­ter J&J-part­nered vac­cine flunks late-stage test

Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs

Agios’ Pyrukynd suc­ceeds in key tri­al of rare red blood cell dis­or­der in kids

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers